Are Peptides Legal? Approved, Compounded and Research-Use-Only Explained
Are Peptides Legal? Approved, Compounded and Research-Use-Only Explained
Peptides fall into three groups. FDA-approved peptide medicines are legal by prescription. Compounded peptides are legal only when the substance is eligible to be compounded and a licensed pharmacy prepares it for a patient's prescription. "Research use only" peptides aren't approved for human use, and the label doesn't make selling them for people legal.
"Are peptides legal?" is one of the most common questions in this category. The honest answer is that it depends on which peptide, how it's made and how it's sold. This explainer covers the three groups. It's educational, not legal advice.
Why peptide legal status confuses audiences
- "Peptide" describes a type of molecule, not a legal category. Some peptides are approved medicines; others aren't approved for any use.
- The same name can appear on a prescription, a compounded preparation and a research vial.
- Regulation changed twice in 2026, and news coverage often oversimplifies it.
FDA-approved peptide medicines
Some peptide medicines are FDA-approved. GLP-1 medications are a familiar example. They're legal with a prescription, dispensed by a pharmacy, and their claims are governed by FDA-approved labeling.
Compounded peptides and the 503A bulks list
Compounding pharmacies prepare medications for individual patients' prescriptions. Under Section 503A, a pharmacy can compound with a bulk substance only if it's eligible, for example by appearing on FDA's 503A bulks list (Category 1) or meeting other conditions.
- In April 2026, FDA removed 12 peptides from Category 2, its list of substances flagged for significant safety risks. That didn't place them in Category 1.
- In July 2026, an FDA advisory committee recommended adding six peptides, including BPC-157, to the list. The vote isn't binding; FDA must still complete rulemaking.
Compounded drugs aren't FDA-approved, and shouldn't be described that way. See our 2026 regulation update.
Research-use-only products and why disclaimers do not protect sellers
"Research use only" products are sold as chemicals for laboratory research. FDA has repeatedly found that the label doesn't protect sellers whose websites show the products are meant for people. In a December 2024 warning letter, for example, FDA rejected "research use only" claims from a seller marketing GLP-1 products for weight loss (FDA).
What this means for affiliate content
Do
- Promote only licensed telehealth programs with clinician review and licensed pharmacies
- Date and source every statement about legal status
- Explain the three groups plainly
Avoid
- Linking to or recommending research-use sellers
- Calling compounded peptides "FDA-approved"
- Describing advisory votes as approval
Frequently asked questions
Are peptides legal?
FDA-approved peptide medicines are legal by prescription. Compounded peptides are legal only when the substance is eligible and a licensed pharmacy prepares it for a prescription. "Research use only" products aren't approved for human use.
What does "research use only" mean?
It's a label for chemicals sold for laboratory research, not for people. FDA has found the label doesn't protect sellers when their marketing shows human use.
Is a compounded peptide FDA-approved?
No. Compounded drugs aren't FDA-approved, even when they're legally prepared by a licensed pharmacy.
Why does the status keep changing?
FDA is reviewing several peptides for compounding eligibility. Changes happen through announcements, advisory committee reviews and rulemaking, so status can shift during the year.
Practical guides and programs for health and beauty publishers.
Educational content for marketers and publishers, not medical, legal or financial advice. Examples labeled hypothetical are illustrations, not results. MarketHealth may earn revenue from programs it describes. See our affiliate disclosure and editorial policy.
Keep reading
Related guides
Peptide Regulation in 2026: What Changed for Publishers
A dated summary of 2026 FDA peptide actions, including the Category 2 change and advisory committee votes, and what publishers can and can't say.
Read guide
Telehealth Peptides vs Research Peptides: Why Publishers Keep Them Separate
Learn why clinician-prescribed telehealth peptides and research-use-only products need separate content, links and programs, and how to keep them apart.
Read guideTelehealth Peptide Content: A Claims Review Guide
Review telehealth peptide affiliate content before publishing: prohibited claims, required disclosures, regulatory-status wording and sources.
Read guide